Last updated on July 2019

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Brief description of study

This is a Phase III/IV, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in participants with Stage IIIb or Stage IV NSCLC who have progressed after standard systemic chemotherapy (including if given in combination with anti-programmed cell death protein 1 [anti-PD-1] therapy, after anti-PD-1 as monotherapy, or after tyrosine kinase inhibitor [TKI] therapy). The study will consist of a Screening Period, a Treatment Period, a Treatment Discontinuation Visit, and a Follow-Up Period.

Clinical Study Identifier: NCT03285763

Find a site near you

Start Over

CETUS Hospital Dia

Belo Horizonte, Brazil
  Connect »

Clinica CIMCA

San Jose, Costa Rica
  Connect »


Guatemala, Guatemala
  Connect »

Meander Medisch Centrum

Amersfoort, Netherlands
  Connect »

UMC Radboud Nijmegen

Nijmegen, Netherlands
  Connect »


Zwolle, Netherlands
  Connect »

Mafraq Hospital; Oncology

Abu Dhabi, United Arab Emirates
  Connect »

Tawam Hospital

Al Ain, United Arab Emirates
  Connect »

Mount Vernon Cancer Centre

Northwood, United Kingdom
  Connect »

New Cross Hospital

Wolverhampton, United Kingdom
  Connect »

Mediclinic City Hospital

Dubai, United Arab Emirates
  Connect »

Beijing Hospital

Beijing City, China
  Connect »

Oncologico Potosino

San Luis Potosí, Mexico
  Connect »